New Two-Pronged drug joins fight against advanced cervical cancer
NCT ID NCT07232654
Summary
This study is testing whether adding a new immunotherapy drug called QL1706 to standard chemotherapy and radiation is safe and more effective for treating locally advanced cervical cancer. It will enroll about 30 women with cancer that has spread locally but not to distant organs. The main goal is to see if this combination helps keep the cancer from progressing for at least two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center/Cancer Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.